Peng Xiao

Dr. Peng Xiao


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
WCWeiwei Cui
Weiwei Cui
MGMeng Guo
Meng Guo
DLDong Liu
Dong Liu
PXPeng Xiao
Peng Xiao
CYChuancheng Yang
Chuancheng Yang
BCBo Chu
Bo Chu

13 April 2022 in Nature
Verified
Journal Article
Closed access
PDF file
PXPeng Xiao
Peng Xiao
SGShengchao Guo
Shengchao Guo
XWXin Wen
Xin Wen
QHQing-Tao He
Qing-Tao He
HLHui Lin
Hui Lin
XYXiao Yu
Xiao Yu

7 April 2023 in Science
Verified
Journal Article
Closed access
CMChunyou Mao
Chunyou Mao
PXPeng Xiao
Peng Xiao
XTXiao-Na Tao
Xiao-Na Tao
JQJiao Qin
Jiao Qin
QHQing-Tao He
Qing-Tao He
JSJinpeng Sun
Jinpeng Sun
Individual free fatty acids (FAs) play important roles in metabolic homeostasis, many through engagement with more than 40G protein–coupled receptors. Searching for receptors to sense beneficial omega-3 FAs of fish oil enabled the identification of GPR120, which is involved in a spectrum of metabolic diseases. Here, we report six cryo–electron microscopy structures of GPR120 in complex with FA hormones or TUG891 and G i or G iq trimers. Aromatic residues inside the GPR120 ligand pocket were responsible for recognizing different double-bond positions of these FAs and connect ligand recognition to distinct effector coupling. We also investigated synthetic ligand selectivity and the structural basis of missense single-nucleotide polymorphisms. We reveal how GPR120 differentiates rigid double bonds and flexible single bonds. The knowledge gleaned here may facilitate rational drug design targeting to GPR120.

29 January 2025 in Cell
Verified
Journal Article
Closed access
ZYZhao Yang
Zhao Yang
YPYu-Qi Ping
Yu-Qi Ping
MWMing-Wei Wang
Ming-Wei Wang
CZChao Zhang
Chao Zhang
SZShu-Hua Zhou
Shu-Hua Zhou
JSJinpeng Sun
Jinpeng Sun

8 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
XTXiao Teng
Xiao Teng
SCSijia Chen
Sijia Chen
YNYingying Nie
Yingying Nie
PXPeng Xiao
Peng Xiao
XYXiao Yu
Xiao Yu
SZSanduo Zheng
Sanduo Zheng
Dopamine receptors are widely distributed in the central nervous system and are important therapeutic targets for treatment of various psychiatric and neurological diseases. Here, we report three cryo-electron microscopy structures of the D1 dopamine receptor (D1R)-Gs complex bound to two agonists, fenoldopam and tavapadon, and a positive allosteric modulator LY3154207. The structure reveals unusual binding of two fenoldopam molecules, one to the orthosteric binding pocket (OBP) and the other to the extended binding pocket (EBP). In contrast, one elongated tavapadon molecule binds to D1R, extending from OBP to EBP. Moreover, LY3154207 stabilizes the second intracellular loop of D1R in an alpha helical conformation to efficiently engage the G protein. Through a combination of biochemical, biophysical and cellular assays, we further show that the broad conformation stabilized by two fenoldopam molecules and interaction between TM5 and the agonist are important for biased signaling of D1R.

8 April 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
WAWentao An
Wentao An
HLHui Lin
Hui Lin
LMLijuan Ma
Lijuan Ma
CZChao Zhang
Chao Zhang
YZYuan Zheng
Yuan Zheng
JSJinpeng Sun
Jinpeng Sun
Significance: The steroid hormone progesterone is highly involved in different physiological–pathophysiological processes, including bone formation and cancer progression. Understanding the working mechanisms, especially identifying the receptors of progesterone hormones, is of great value. In the present study, we identified GPR126 as a membrane receptor for both progesterone and 17-hydroxyprogesterone and triggered its downstream G protein signaling. We further characterized the residues of GPR126 that interact with these two ligands and found that progesterone promoted the progression of a triple-negative breast cancer model through GPR126-dependent Gi-SRC signaling. Therefore, developing antagonists targeting GPR126-Gi may provide an alternative therapeutic option for patients with triple-negative breast cancer.